Imidazo[1,2-a]pyrazines as novel PI3K inhibitors.

Abstract Phosphoinositide-3-kinase (PI3K) is an important target for cancer therapeutics due to the deregulation of its signaling pathway in a wide variety of human cancers. We describe herein a novel series of imidazo[1,2- a ]pyrazines as PI3K inhibitors.